Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALPG | P10696 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11462125 | 0.88 | SMN1; SMN2 (0.53) | CTSLCTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL3146429 | 0.87 | MAPT (0.58) | SMN1; SMN2LMNAHPGDALDH1A1HTT | |
| SCHEMBL94130 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAHPGDALDH1A1HTT | |
| SCHEMBL7531909 | 0.85 | MEN1 (0.57) | CTSLSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL11227919 | 0.84 | SRD5A2 (0.51) | SMN1; SMN2LMNAHPGDALDH1A1PTGS1 | |
| Water SCHEMBL11470792 | 0.84 | SMN1; SMN2 (0.46) | CTSLCTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL11227216 | 0.83 | CES2 (0.42) | PARP1KMT2AMAPK14 | |
| SCHEMBL10999133 | 0.79 | MAPK14 (0.40) | CTSLSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL10952091 | 0.79 | SMN1; SMN2 (0.46) | CTSLCTSKSMN1; SMN2LMNAHPGD | |
| SCHEMBL1354525 | 0.79 | HDAC4 (0.51) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101426487-B | Formulations containing amide derivatives of carboxylic acidnsaids for topical administration to the eye | ALCON INC | 2011-04-06 | — | — | CN | claimed |
| CN-101426487-A | Formulations containing amide derivatives of carboxylic acidnsaids for topical administration to the eye | ALCON INC (CH) | 2009-05-06 | — | — | CN | claimed |
| EP-2012767-A2 | FORMULATIONS CONTAINING AMIDE DERIVATIVES OF CARBOXYLIC ACID NSAIDS FOR TOPICAL ADMINISTRATION TO THE EYE | ALCON INC. (CH) | 2009-01-14 | — | — | EP | claimed |
| WO-2007127844-A2 | FORMULATIONS CONTAINING AMIDE DERIVATIVES OF CARBOXYLIC ACID NSAIDS FOR TOPICAL ADMINISTRATION TO THE EYE | ALCON, INC. (CH) | 2007-11-08 | — | — | WO | claimed |
| US-20070254939-A1 | Formulations Containing Amide Derivatives of Carboxylic Acid NSAIDS for Topical Administration to the Eye | ALCON, INC. (CH) | 2007-11-01 | — | — | US | claimed |
| EP-1309323-B1 | TREATMENT OF ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID DERIVATIVES | ALCON INC (CH) | 2006-11-15 | — | — | EP | claimed |
| EP-1309322-B1 | USE OF 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISORDERS | ALCON INC (CH) | 2006-06-21 | — | — | EP | claimed |
| JP-2004520267-A | — | — | 2004-07-08 | — | — | JP | claimed |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALCON, INC. (CH) | 2004-07-08 | — | — | US | claimed |
| US-6646001-B2 | Administering to a glaucoma affected eye a combination of an intraocular pressure lowering prostaglandin FP receptor agonist, and a prostaglandin synthesis inhibitor other than diclofenac or fluorometholone | ALCON MANUFACTURING, LTD. | 2003-11-11 | — | — | US | claimed |
| EP-0716600-B1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LAB INC (US) | 2002-04-03 | — | — | EP | claimed |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | ALCON UNIVERSAL LTD. | 2002-03-28 | — | — | US | claimed |
| WO-2002013805-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | claimed |
| WO-2002013804-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | claimed |
| US-6342524-B1 | TREATMENT OF GLAUCOMA WITH PROSTAGLANDINS | ALCON MANUFACTURING, LTD. | 2002-01-29 | — | — | US | claimed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | claimed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | claimed |
| US-4313949-A | Method of producing an inhibitory effect on blood platelet aggregation | A. H. ROBINS COMPANY, INC. (US) | 1982-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALDH1A2, GAP43, NLN | CTSL 1987/4885CTSK 1241/4885SMN1; SMN2 467/4885 |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | CTSL 1278/4885CTSK 1116/4885SMN1; SMN2 3172/4885 |
| US-20070254939-A1 | Formulations Containing Amide Derivatives of Carboxylic Acid NSAIDS for Topical Administration to the Eye | NDUFAB1, CS, SLC25A1 | CTSL 1765/4885CTSK 1337/4885SMN1; SMN2 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.